October 24, 2017 06:59 AM EDT

AbbVie antes up $225M in cash to buy into the Alzheimer's platform at Alector

John Carroll

Editor & Founder

For well over a decade now, the major focus in Alzheimer’s R&D has been concentrating heavily — though not exclusively — on the tangles of toxic amyloid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie antes up $225M in cash to buy into the Alzheimer's platform at Alector

John Carroll

Editor & Founder

Sign up to read this article for free.

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

Gilead names Dietmar Berger CMO as it eyes R&D reset

The key to faster, more impactful research? Put patients in the driver’s seat

Ab­b­Vie antes up $225M in cash to buy in­to the Alzheimer's plat­form at Alec­tor

John Carroll

Editor & Founder

Sign up to read this article for free.

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

AbbVie antes up $225M in cash to buy into the Alzheimer's platform at Alector

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

Gilead names Dietmar Berger CMO as it eyes R&D reset

The key to faster, more impactful research? Put patients in the driver’s seat